$ALNY News

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation

ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $375

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $300

Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $316

Stifel Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $318

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ...

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript

Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $357

Alnylam Pharmaceuticals Q2 Earnings Call Highlights

Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Alnylam Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates

Alnylam Pharmaceuticals (NASDAQ:ALNY) Plunges After Q2 Revenue Miss and Lowered Full-Year Guidance

Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est